Preferred Label : HPV 16/18 E6/E7/HSP70 Plasmid DNA Prime Vaccine pBI-11/HPV 16/18 E6/E7 Vaccinia Boost
Vaccine TA-HPV PVX7;
NCIt synonyms : Prime/Boost HPV Vaccine PVX7; Therapeutic HPV Vaccine PVX7; DNA Prime Vaccine pBI-11/Vaccinia Viral Vector Boost Vaccine TA-HPV PVX7; pBI-11 DNA Prime Followed by TA-HPV Vaccinia Boost Vaccine PVX7; pBI-11 DNA Plus TA-HPV; pBI-11 Plus TA-HPV Vaccine PVX7; HPV 16/18 E6/E7/HSP70 DNA Vaccine pBI-11/HPV 16/18 E6/E7 Vaccinia Vaccine TA-HPV PVX7;
NCIt definition : A therapeutic prime/boost cancer vaccine consisting of PVX7, which is a combination
of two vaccines: the pBI-11 prime vaccine, a therapeutic codon-optimized plasmid DNA
vaccine encoding for the E6 and E7 oncoproteins of the human papillomavirus (HPV)
subtypes 16 (HPV16) and 18 (HPV18) fused with heat shock protein 70 (HSP70), and the
HPV tumor antigen (TA-HPV) boost vaccine, a recombinant vaccinia viral vector-based
vaccine encoding epitopes of the E6 and E7 oncoproteins from HPV16 and HPV18, with
potential immunostimulating and antineoplastic activities. The pBI-11 DNA prime vaccine
is administered first followed by the TA-HPV boost vaccine. Upon administration, the
HPV 16/18 E6/E7/HSP70 DNA vaccine pBI-11 part of PVX7 expresses the HPV 16/18 E6/E7
fusion protein, which may elicit the host immune system to mount a specific cytotoxic
T-lymphocyte (CTL) response against cancer cells expressing the HPV 16/18 E6 and E7
oncoproteins, resulting in tumor cell lysis. Upon administration of the TA-HPV vaccinia
vaccine part of PVX7, the HPV16 E6/E7 and the HPV18 E6/E7 may boost the host immune
system to mount a specific CTL response against cancer cells expressing the HPV 16/18
E6 and E7 oncoproteins, thereby further killing these cancer cells. HSP70 enhances
antigen presentation of pBI-11.;
Molecule name : PVX 7; PVX-7;
Origin ID : C212077;
concept_is_in_subset
- has_target
